
Robert Driscoll
Stock Analyst at Wedbush
(2.06)
# 3,258
Out of 5,189 analysts
420
Total ratings
33.4%
Success rate
0.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Driscoll
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IDYA IDEAYA Biosciences | Maintained: Buy | $63 | $25.56 | +146.48% | 30 | Nov 18, 2026 | |
| CGON CG Oncology | Reiterated: Buy | $84 → $91 | $79.47 | +14.51% | 6 | Nov 17, 2026 | |
| EIKN Eikon Therapeutics | Reiterated: Sell | $5 → $4 | $4.74 | -15.61% | 4 | Nov 13, 2026 | |
| ZNTL Zentalis Pharmaceuticals | Upgraded: Buy | $4 → $6 | $1.36 | +341.18% | 14 | Nov 10, 2026 | |
| CGEM Cullinan Therapeutics | Reiterated: Buy | $42 | $8.89 | +372.44% | 24 | Nov 9, 2026 | |
| ACET Adicet Bio | Reiterated: Buy | $28 | $2.14 | +1,208.41% | 14 | Nov 6, 2026 | |
| AVTX Avalo Therapeutics | Reiterated: Buy | $22 → $20 | $6.76 | +195.86% | 6 | Nov 6, 2026 | |
| CTMX CytomX Therapeutics | Reiterated: Buy | $11 → $12 | $2.03 | +491.13% | 19 | Nov 6, 2026 | |
| GLUE Monte Rosa Therapeutics | Reiterated: Buy | $27 | $8.64 | +212.50% | 14 | Nov 6, 2026 | |
| JANX Janux Therapeutics | Reiterated: Buy | $36 → $40 | $10.08 | +296.83% | 13 | Nov 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 → $7 | $1.81 | +286.74% | 4 | Nov 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $0.8707 | +474.25% | 17 | Nov 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $43 → $45 | $15.62 | +188.09% | 27 | Nov 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $225 | $161.20 | +39.58% | 27 | Nov 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $12 | $6.46 | +85.76% | 29 | Nov 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $19 | $19.07 | -0.37% | 23 | Oct 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $27 | $13.00 | +107.69% | 8 | Oct 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $10 → $2 | $1.72 | +16.28% | 16 | Oct 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $8 → $1 | $0.6882 | +45.31% | 5 | Sep 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $2.06 | +1,356.31% | 7 | Sep 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $53 | $20.12 | +163.42% | 17 | Sep 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $33 → $39 | $21.73 | +79.48% | 12 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 | $1.31 | +968.70% | 15 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $36 | $6.91 | +420.98% | 31 | Jul 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 → $6 | $0.229 | +2,520.09% | 8 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $6 → $1 | $0.9466 | +5.64% | 4 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $27 | $4.21 | n/a | 1 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $8 → $1.6 | - | n/a | 10 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $67 | $166.43 | n/a | 1 | Nov 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 → $6 | $4.02 | n/a | 8 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $9.67 | n/a | 4 | Oct 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $7 → $10 | $0.0001 | n/a | 2 | Mar 19, 2020 |
IDEAYA Biosciences
Nov 18, 2026
Maintained: Buy
Price Target: $63
Current: $25.56
Upside: +146.48%
CG Oncology
Nov 17, 2026
Reiterated: Buy
Price Target: $84 → $91
Current: $79.47
Upside: +14.51%
Eikon Therapeutics
Nov 13, 2026
Reiterated: Sell
Price Target: $5 → $4
Current: $4.74
Upside: -15.61%
Zentalis Pharmaceuticals
Nov 10, 2026
Upgraded: Buy
Price Target: $4 → $6
Current: $1.36
Upside: +341.18%
Cullinan Therapeutics
Nov 9, 2026
Reiterated: Buy
Price Target: $42
Current: $8.89
Upside: +372.44%
Adicet Bio
Nov 6, 2026
Reiterated: Buy
Price Target: $28
Current: $2.14
Upside: +1,208.41%
Avalo Therapeutics
Nov 6, 2026
Reiterated: Buy
Price Target: $22 → $20
Current: $6.76
Upside: +195.86%
CytomX Therapeutics
Nov 6, 2026
Reiterated: Buy
Price Target: $11 → $12
Current: $2.03
Upside: +491.13%
Monte Rosa Therapeutics
Nov 6, 2026
Reiterated: Buy
Price Target: $27
Current: $8.64
Upside: +212.50%
Janux Therapeutics
Nov 6, 2026
Reiterated: Buy
Price Target: $36 → $40
Current: $10.08
Upside: +296.83%
Nov 6, 2026
Reiterated: Buy
Price Target: $6 → $7
Current: $1.81
Upside: +286.74%
Nov 5, 2026
Reiterated: Buy
Price Target: $5
Current: $0.8707
Upside: +474.25%
Nov 5, 2026
Reiterated: Buy
Price Target: $43 → $45
Current: $15.62
Upside: +188.09%
Nov 5, 2026
Reiterated: Buy
Price Target: $225
Current: $161.20
Upside: +39.58%
Nov 4, 2026
Reiterated: Hold
Price Target: $12
Current: $6.46
Upside: +85.76%
Oct 29, 2026
Reiterated: Buy
Price Target: $19
Current: $19.07
Upside: -0.37%
Oct 5, 2026
Reiterated: Buy
Price Target: $27
Current: $13.00
Upside: +107.69%
Oct 2, 2026
Downgraded: Hold
Price Target: $10 → $2
Current: $1.72
Upside: +16.28%
Sep 23, 2026
Downgraded: Hold
Price Target: $8 → $1
Current: $0.6882
Upside: +45.31%
Sep 15, 2026
Reiterated: Buy
Price Target: $30
Current: $2.06
Upside: +1,356.31%
Sep 11, 2026
Reiterated: Buy
Price Target: $53
Current: $20.12
Upside: +163.42%
Aug 12, 2026
Reiterated: Buy
Price Target: $33 → $39
Current: $21.73
Upside: +79.48%
Aug 6, 2026
Reiterated: Buy
Price Target: $14
Current: $1.31
Upside: +968.70%
Jul 28, 2026
Reiterated: Buy
Price Target: $36
Current: $6.91
Upside: +420.98%
May 14, 2026
Reiterated: Buy
Price Target: $7 → $6
Current: $0.229
Upside: +2,520.09%
Dec 19, 2025
Downgraded: Hold
Price Target: $6 → $1
Current: $0.9466
Upside: +5.64%
Jul 14, 2025
Initiated Coverage: Buy
Price Target: $27
Current: $4.21
Upside: n/a
Mar 20, 2025
Downgraded: Hold
Price Target: $8 → $1.6
Current: -
Upside: n/a
Nov 19, 2021
Reiterated: Buy
Price Target: $67
Current: $166.43
Upside: n/a
Mar 8, 2021
Reiterated: Buy
Price Target: $7 → $6
Current: $4.02
Upside: n/a
Oct 5, 2020
Reiterated: Buy
Price Target: $8
Current: $9.67
Upside: n/a
Mar 19, 2020
Downgraded: Hold
Price Target: $7 → $10
Current: $0.0001
Upside: n/a